All Pharma News
Organovo Shows FXR314 IBD Combination Potential At DDW2024

Organovo Shows FXR314 IBD Combination Potential At DDW2024
GLOBENEWSWIRE
21 May 2024
Share Share
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
GLOBENEWSWIRE
08 May 2024
Share Share
Organovo To Present FXR314 IBD 3D Model Findings at Crohn™s and Colitis Congress

Organovo To Present FXR314 IBD 3D Model Findings at Crohn™s and Colitis Congress
GLOBENEWSWIRE
09 Jan 2024
Share Share
CORRECTION “ Organovo Highlights FXR314 Combination Therapy Potential and Plan

CORRECTION “ Organovo Highlights FXR314 Combination Therapy Potential and Plan
GLOBENEWSWIRE
13 Nov 2023
Share Share
Organovo to Participate in the H.C. Wainwright Global Investment Conference

Organovo to Participate in the H.C. Wainwright Global Investment Conference
GLOBENEWSWIRE
08 Sep 2023
Share Share
Organovo Advances Clinical Timelines for FXR314

Organovo Advances Clinical Timelines for FXR314
GLOBENEWSWIRE
23 Aug 2023
Share Share
Organovo Announces FXR Program

Organovo Announces FXR Program
GLOBENEWSWIRE
21 Mar 2023
Share Share
Organovo Announces Accelerating Timeline for Crohn’s Drug Candidates

Organovo Announces Accelerating Timeline for Crohn’s Drug Candidates
GLOBENEWSWIRE
15 Nov 2022
Share Share
Organovo to Participate in the H.C. Wainwright 24th AnnualGIC

Organovo to Participate in the H.C. Wainwright 24th AnnualGIC
GLOBENEWSWIRE
06 Sep 2022
Share Share
Organovo Achieves 3D Tissue Model for Crohn`s Disease

Organovo Achieves 3D Tissue Model for Crohn`s Disease
GLOBENEWSWIRE
17 May 2022
Share Share